New England Journal of Medicine (2025) The REDEFINE 2 Phase 3 trial evaluated CagriSema in 1,206 adults with overweight or obesity and type 2 diabetes in a 68-week, double-blind, placebo-controlled design
Temporarily increase BPC-157 to 500 mcg twice daily during flares Increase cryotherapy frequency to daily application Reduce activity level until flare subsides Return to maintenance protocol once symptoms stabilize Athletic Performance Maintenance Preventive approach during heavy training blocks
[DOI] [PMC free article] [PubMed] [Google Scholar] 35.Aamodt WW, Waligorska T, Shen J, Tropea TF, Siderowf A, Weintraub D, Grossman M, Irwin D, Wolk DA, Xie SX, Trojanowski JQ, Shaw LM, Chen-Plotkin AS
Infection rare with proper technique but serious complication when occurs